Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JCTC
2801
Jewett-Cameron Trading
JCTC
$10.2M
| $639K | ﹤0.01% |
112,028
-10,500
| -9% | -$55K |
|
|
IVC
2802
DELISTED
Invacare Corporation
IVC
| $639K | ﹤0.01% |
1,521,569
-125,700
| -8% | -$67.6K |
|
2803
Heritage Insurance Holdings
HRTG
$1.01B
| $638K | ﹤0.01% |
354,599
+115,700
| +48% | +$191K |
|
|
KALV
2804
DELISTED
KalVista Pharmaceuticals
KALV
| $637K | ﹤0.01% |
94,300
-29,800
| -24% | -$160K |
|
2805
Farmers & Merchants Bancorp
FMAO
$483M
| $635K | ﹤0.01% |
23,381
-16,000
| -41% | -$451K |
|
2806
CVD Equipment Corp
CVV
$56M
| $634K | ﹤0.01% |
115,082
-11,300
| -9% | -$63.1K |
|
2807
Vanguard Russell 2000 ETF
VTWO
$17.6B
| $633K | ﹤0.01% |
+9,000
| New | +$647K |
|
|
KNTE
2808
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $631K | ﹤0.01% |
103,400
+2,900
| +3% | +$23.6K |
|
2809
Village Farms International
VFF
$309M
| $629K | ﹤0.01% |
469,100
+219,439
| +88% | +$418K |
|
|
AZEK
2810
DELISTED
The AZEK Co
AZEK
| $628K | ﹤0.01% |
30,900
-218,000
| -88% | -$4.03M |
|
|
UBFO
2811
DELISTED
United Security Bancshares
UBFO
| $627K | ﹤0.01% |
85,748
+989
| +1% | +$6.88K |
|
2812
Gyre Therapeutics
GYRE
$708M
| $626K | ﹤0.01% |
158,265
+11,429
| +8% | +$46.6K |
|
2813
RBB Bancorp
RBB
$467M
| $626K | ﹤0.01% |
+30,000
| New | +$653K |
|
|
GVP
2814
DELISTED
GSE Systems, Inc.
GVP
| $626K | ﹤0.01% |
86,908
+2,643
| +3% | +$19.9K |
|
2815
Alico
ALCO
$297M
| $625K | ﹤0.01% |
26,191
-35,905
| -58% | -$1.04M |
|
2816
Geron
GERN
$943M
| $624K | ﹤0.01% |
257,800
+24,100
| +10% | +$54K |
|
2817
iShares MSCI Thailand ETF
THD
$353M
| $624K | ﹤0.01% |
8,300
+2,300
| +38% | +$160K |
|
|
ADVM
2818
DELISTED
Adverum Biotechnologies
ADVM
| $623K | ﹤0.01% |
107,424
-4,420
| -4% | -$33.5K |
|
2819
GraniteShares Gold Shares
BAR
$1.47B
| $623K | ﹤0.01% |
34,500
-150,100
| -81% | -$2.57M |
|
2820
iShares Global Tech ETF
IXN
$9.42B
| $623K | ﹤0.01% |
+13,900
| New | +$634K |
|
|
CARM
2821
DELISTED
Carisma Therapeutics
CARM
| $621K | ﹤0.01% |
50,948
-1,842
| -3% | -$19.3K |
|
2822
SEACOR Marine Holdings
SMHI
$268M
| $620K | ﹤0.01% |
67,700
-3,400
| -5% | -$26.4K |
|
2823
Lesaka Technologies
LSAK
$407M
| $619K | ﹤0.01% |
136,100
+1,100
| +0.8% | +$4.34K |
|
|
TDAY
2824
USA Today Co
TDAY
$1.03B
| $618K | ﹤0.01% |
304,200
-16,724
| -5% | -$32.1K |
|
2825
Neuronetics
STIM
$230M
| $618K | ﹤0.01% |
89,900
-77,121
| -46% | -$364K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.